Track topics on Twitter Track topics that are important to you
Praxis Bioresearch said today it has won a $1.5 million Fast-Track Small Business Innovation Research (SBIR) grant from the NIH toward ongoing development of the company’s lead product candidate PRX-P4-003, a prodrug stimulant designed to significantly reduce the risk of abuse. PRX-P4-003 is a novel, abuse-deterrent dopamine norepinephrine reuptake inhibitor incorporating an active isomer of fencamfamine (FCF). FCF is a Schedule IV stimulant that has been prescribed for decades in Europe and elsewhere overseas, primarily for depressive daytime fatigue, lack of concentration, and lethargy. According to Praxis, PRX-P4-003 is specifically designed to produce therapeutic stimulant activity when delivered orally—but not if illicitly injected—since PRX-P4-003 is a substrate of pancreatic lipase, an enzyme whose activity is almost entirely restricted to the gut. That minimizes the potential for its oral abuse, the company reasons. In a study presented at the 2017 Annual Meeting of the American College of Neuropsychopharmacology, ...NEXT ARTICLE
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake. Diagnosis is based on clinical presentation...
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...